Stockpolly
Search

Categories·Biotech·New Drug Development

Oncology Biopharmaceuticals

−4.19% today·181 stocks

Stocks

By market cap · 181 stocks

  1. 1Revolution MedicinesRVMDDeveloper of RAS(ON) oncology candidates$44.19B−5.91%
  2. 2BeOne Medicines (ADR)ONCDeveloper of BRUKINSA and TEVIMBRA oncology medicines$39.19B−1.54%
  3. 3BioNTech (ADR)BNTXComirnaty developer with an oncology pipeline$25.64B−8.36%
  4. 4Genmab (ADR)GMABBuilder of antibody medicines and bispecific platforms$20.40B−2.58%
  5. 5ExelixisEXELBuilder of the cabozantinib oncology franchise$13.69B−1.52%
  6. 6ImmunityBioIBRXMaker of ANKTIVA and cellular immunotherapies$8.43B−4.17%
  7. 7CG OncologyCGONCretostimogene developer and contract manufacturer$6.56B−5.92%
  8. 8ErascaERASDeveloper of pan-RAS and pan-KRAS cancer drugs$6.26B−7.47%
  9. 9Enliven TherapeuticsELVNDeveloper of ELVN-001 for chronic myeloid leukemia$4.13B−4.38%
  10. 10Relay TherapeuticsRLAYProtein-motion medicines for cancer and genetic disease$4.11B−3.40%
  11. 11Telix PharmaceuticalsTLXProstate imaging products and cancer radiopharmaceutical platform$3.82B−0.92%
  12. 12IDEAYA BiosciencesIDYABiomarker-selected cancer drug developer$3.81B−3.93%
  13. 13Tango TherapeuticsTNGXDeveloper of MTAP-selective PRMT5 cancer drugs$3.80B−7.59%
  14. 14Legend Biotech (ADR)LEGNCARVYKTI commercializer and CAR-T developer$3.68B−3.05%
  15. 15Arcus BiosciencesRCUSDeveloper of casdatifan and oral inflammation drugs$3.67B−4.58%
  16. 16Iovance BiotherapeuticsIOVACommercial TIL therapy for solid tumors$3.58B−2.85%
  17. 17Nurix TherapeuticsNRIXTargeted protein degradation drug developer$2.72B−2.55%
  18. 18Celldex TherapeuticsCLDXMast-cell antibody developer for inflammatory diseases$2.60B−3.39%
  19. 19BioCryst PharmaceuticalsBCRXRare-disease therapies centered on hereditary angioedema$2.50B−0.51%
  20. 20SELLAS Life Sciences GroupSLSDeveloper of GPS and SLS009 oncology candidates$2.46B−13.35%
  21. 21Nuvation BioNUVBOncology developer behind IBTROZI$2.31B−4.72%
  22. 22UroGen PharmaURGNRTGel uro-oncology drug developer$2.13B−4.11%
  23. 23Nanobiotix (ADR)NBTXDeveloper of radiotherapy-activated nanoparticle candidates$2.09B−9.03%
  24. 24ZymeworksZYMEDeveloper of antibody medicines and royalty assets$2.08B−2.55%
  25. 25XencorXNCRDesigner of Fc-engineered, bispecific antibody drug candidates$1.93B−9.87%
  26. 26Inhibrx BiosciencesINBXBiologic developer behind ozekibart and INBRX-106$1.81B−0.23%
  27. 27Syndax PharmaceuticalsSNDXTargeted therapies for leukemia and chronic GVHD$1.73B−3.08%
  28. 28Bicara TherapeuticsBCAXDeveloper of bifunctional cancer antibodies$1.54B−5.70%
  29. 29Tyra BiosciencesTYRAOral FGFR drug developer for cancer and achondroplasia$1.49B−4.34%
  30. 30ArriVent BioPharmaAVBPDeveloper of EGFR and ADC cancer candidates$1.41B−2.52%
  31. 31Aktis OncologyAKTSMiniprotein radioconjugates for solid tumors$1.38B−1.59%
  32. 32ORIC PharmaceuticalsORICClinical-stage developer of resistance-targeted cancer therapies$1.37B−3.71%
  33. 33Cullinan TherapeuticsCGEMT-cell engager developer for autoimmune disease and cancer$1.33B−4.07%
  34. 34Alpha Tau MedicalDRTSDeveloper of localized Alpha DaRT cancer therapy$1.32B−0.95%
  35. 35Replimune GroupREPLHSV-1 oncolytic immunotherapy developer$1.30B−0.58%
  36. 36ImmaticsIMTXPRAME-focused T-cell therapy developer$1.27B+0.85%
  37. 37Vor BiopharmaVORDeveloper of licensed telitacicept for autoimmune disease$1.23B−3.74%
  38. 38Corvus PharmaceuticalsCRVSSoquelitinib-centered clinical immunotherapy developer$1.19B−3.91%
  39. 39KuraKURAKOMZIFTI-centered oncology drug developer$1.12B−4.10%
  40. 40Janux TherapeuticsJANXEngineers tumor-activated bispecific antibodies for cancer$1.10B−4.10%
  41. 41Candel TherapeuticsCADLDeveloper of off-the-shelf viral cancer immunotherapies$957.6M−5.02%
  42. 42Olema PharmaceuticalsOLMADeveloper of endocrine cancer therapies$897.1M−4.73%
  43. 43Faeth TherapeuticsFTHPIKTOR cancer-therapy developer$872.4M−0.18%
  44. 44Aura BiosciencesAURAVirus-like conjugates for organ-preserving oncology$765.4M−3.96%
  45. 45Immix BiopharmaIMMXDeveloper of NXC-201 CAR-T therapy$758.4M−2.73%
  46. 46Monopar TherapeuticsMNPRWilson disease and radiopharmaceutical developer$749.6M−1.36%
  47. 47Adlai Nortye (ADR)ANLDeveloper of RAS and cancer immunotherapy candidates$733.6M−4.05%
  48. 48BridgeBio Oncology TherapeuticsBBOTSmall molecules for RAS and PI3K cancers$700.1M−5.01%
  49. 49CytomX TherapeuticsCTMXDeveloper of PROBODY-masked oncology biologics$698.8M−5.99%
  50. 50Allogene TherapeuticsALLOOff-the-shelf CAR T cell developer$697.2M−3.59%